Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.4
Journals
BioTech
Special Issues
Feature Papers in Medical Biotechnology
share announcement

Feature Papers in Medical Biotechnology

A special issue of BioTech (ISSN 2673-6284). This special issue belongs to the section "Medical Biotechnology".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 7503

Special Issue Editors

Dr. Jose Caparros-Martin

E-Mail Website
Guest Editor
Faculty of Health Sciences & Curtin Health Innovation Research Institute (CHIRI), Curtin University, Bentley, WA 6102, Australia
Interests: host–microbiota interaction; gut–lung axis
Special Issues, Collections and Topics in MDPI journals
Dr. Tomoaki Kahyo

E-Mail Website
Guest Editor
Department of Cellular & Molecular Anatomy, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka 431-3192, Japan
Interests: imaging mass spectrometry; omics analysis; cell engineering

Special Issue Information

Dear Colleagues,

This Special Issue aims to publish high-quality articles covering topics related to the latest research and developments in the field of medical biotechnology. Potential topics include, but are not limited to, the following:

  • Genetic engineering;
  • CRISPR technology;
  • Recombinant DNA technology;
  • Gene sequencing;
  • Antibody production;
  • Pharmaceutical products;
  • Drug design;
  • Drug delivery system;
  • Cell culture;
  • Disease diagnosis and treatment;
  • Molecular diagnostics;
  • Protein therapeutics;
  • Gene therapy;
  • Vaccines production;
  • Tumor models;
  • Cell and tissue engineering;
  • In vivo imaging;
  • Biomolecule imaging;
  • Medical and ethical issues.

You are welcome to send short proposals for submissions of feature papers to our Editorial Office (biotech@mdpi.com). They will be evaluated by editors, and the selected papers will be thoroughly and rigorously peer reviewed.

Dr. Jose Caparros-Martin
Dr. Tomoaki Kahyo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. BioTech is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

7 pages, 1127 KiB  
Communication
Development of the Follow-Up Human 3D Oral Cancer Model in Cancer Treatment
by Kazuyo Igawa, Kenji Izumi and Yoshinori Sakurai
BioTech 2023, 12(2), 35; https://doi.org/10.3390/biotech12020035 - 11 May 2023
Viewed by 1714
Abstract
As function preservation cancer therapy, targeted radiation therapies have been developed for the quality of life of cancer patients. However, preclinical animal studies evaluating the safety and efficacy of targeted radiation therapy is challenging from the viewpoints of animal welfare and animal protection, [...] Read more.
As function preservation cancer therapy, targeted radiation therapies have been developed for the quality of life of cancer patients. However, preclinical animal studies evaluating the safety and efficacy of targeted radiation therapy is challenging from the viewpoints of animal welfare and animal protection, as well as the management of animal in radiation-controlled areas under the regulations. We fabricated the human 3D oral cancer model that considers the time axis of the follow up in cancer treatment. Therefore, in this study, the 3D model with human oral cancer cells and normal oral fibroblasts was treated based on clinical protocol. After cancer treatment, the histological findings of the 3D oral cancer model indicated the clinical correlation between tumor response and surrounding normal tissue. This 3D model has potential as a tool for preclinical studies alternative to animal studies. Full article
(This article belongs to the Special Issue Feature Papers in Medical Biotechnology)
►▼ Show Figures

Figure 1

14 pages, 4062 KiB  
Article
Computational Screening of Approved Drugs for Inhibition of the Antibiotic Resistance Gene mecA in Methicillin-Resistant Staphylococcus aureus (MRSA) Strains
by Benson Otarigho and Mofolusho O. Falade
BioTech 2023, 12(2), 25; https://doi.org/10.3390/biotech12020025 - 31 Mar 2023
Cited by 2 | Viewed by 2471
Abstract
Antibiotic resistance is a critical problem that results in a high morbidity and mortality rate. The process of discovering new chemotherapy and antibiotics is challenging, expensive, and time-consuming, with only a few getting approved for clinical use. Therefore, screening already-approved drugs to combat [...] Read more.
Antibiotic resistance is a critical problem that results in a high morbidity and mortality rate. The process of discovering new chemotherapy and antibiotics is challenging, expensive, and time-consuming, with only a few getting approved for clinical use. Therefore, screening already-approved drugs to combat pathogens such as bacteria that cause serious infections in humans and animals is highly encouraged. In this work, we aim to identify approved antibiotics that can inhibit the mecA antibiotic resistance gene found in methicillin-resistant Staphylococcus aureus (MRSA) strains. The MecA protein sequence was utilized to perform a BLAST search against a drug database containing 4302 approved drugs. The results revealed that 50 medications, including known antibiotics for other bacterial strains, targeted the mecA antibiotic resistance gene. In addition, a structural similarity approach was employed to identify existing antibiotics for S. aureus, followed by molecular docking. The results of the docking experiment indicated that six drugs had a high binding affinity to the mecA antibiotic resistance gene. Furthermore, using the structural similarity strategy, it was discovered that afamelanotide, an approved drug with unclear antibiotic activity, had a strong binding affinity to the MRSA-MecA protein. These findings suggest that certain already-approved drugs have potential in chemotherapy against drug-resistant pathogenic bacteria, such as MRSA. Full article
(This article belongs to the Special Issue Feature Papers in Medical Biotechnology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

23 pages, 3365 KiB  
Review
Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
by Vehary Sakanyan, Nina Iradyan and Rodolphe Alves de Sousa
BioTech 2023, 12(3), 57; https://doi.org/10.3390/biotech12030057 - 06 Sep 2023
Viewed by 2602
Abstract
Targeted protein degradation is an attractive technology for cancer treatment due to its ability to overcome the unpredictability of the small molecule inhibitors that cause resistance mutations. In recent years, various targeted protein degradation strategies have been developed based on the ubiquitin–proteasome system [...] Read more.
Targeted protein degradation is an attractive technology for cancer treatment due to its ability to overcome the unpredictability of the small molecule inhibitors that cause resistance mutations. In recent years, various targeted protein degradation strategies have been developed based on the ubiquitin–proteasome system in the cytoplasm or the autophagy–lysosomal system during endocytosis. In this review, we describe and compare technologies for the targeted inhibition and targeted degradation of the epidermal growth factor receptor (EGFR), one of the major proteins responsible for the onset and progression of many types of cancer. In addition, we develop an alternative strategy, called alloAUTO, based on the binding of new heterocyclic compounds to an allosteric site located in close proximity to the EGFR catalytic site. These compounds cause the targeted degradation of the transmembrane receptor, simultaneously activating both systems of protein degradation in cells. Damage to the EGFR signaling pathways promotes the inactivation of Bim sensor protein phosphorylation, which leads to the disintegration of the cytoskeleton, followed by the detachment of cancer cells from the extracellular matrix, and, ultimately, to cancer cell death. This hallmark of targeted cancer cell death suggests an advantage over other targeted protein degradation strategies, namely, the fewer cancer cells that survive mean fewer chemotherapy-resistant mutants appear. Full article
(This article belongs to the Special Issue Feature Papers in Medical Biotechnology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop